Cargando…
Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/E...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540032/ https://www.ncbi.nlm.nih.gov/pubmed/34696254 http://dx.doi.org/10.3390/vaccines9101146 |
_version_ | 1784588889550225408 |
---|---|
author | Levin, Myron J. Divino, Victoria Shah, Drishti DeKoven, Mitch Mould-Quevedo, Joaquin Pelton, Stephen I. Postma, Maarten J. |
author_facet | Levin, Myron J. Divino, Victoria Shah, Drishti DeKoven, Mitch Mould-Quevedo, Joaquin Pelton, Stephen I. Postma, Maarten J. |
author_sort | Levin, Myron J. |
collection | PubMed |
description | The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/ER visits among adults ≥65 years during the 2019–2020 influenza season. Economic outcomes were also compared. A retrospective cohort analysis was conducted using prescription, professional fee claims, and hospital data. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. IPTW-adjusted Poisson regression was used to evaluate the adjusted rVE of aIIV3 versus HD-IIV3e. All-cause and influenza-related healthcare resource utilization (HCRU) and costs were examined post-IPTW. Recycled predictions from generalized linear models were used to estimate adjusted costs. Adjusted analysis showed that aIIV3 (n = 798,987) was similarly effective compared to HD-IIV3e (n = 1,655,979) in preventing influenza-related hospitalizations/ER visits (rVE 3.1%; 95% CI: −2.8%; 8.6%), hospitalizations due to any cause (−0.7%; 95% CI: −1.6%; 0.3%), and any CRD-related hospitalization/ER visit (0.9%; 95% CI: 0.01%; 1.7%). Adjusted HCRU and annualized costs were also statistically insignificant between the two cohorts. The adjusted clinical and economic outcomes evaluated in this study were comparable between aIIV3 and HD-IIV3e during the 2019–2020 influenza season. |
format | Online Article Text |
id | pubmed-8540032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85400322021-10-24 Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis Levin, Myron J. Divino, Victoria Shah, Drishti DeKoven, Mitch Mould-Quevedo, Joaquin Pelton, Stephen I. Postma, Maarten J. Vaccines (Basel) Article The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/ER visits among adults ≥65 years during the 2019–2020 influenza season. Economic outcomes were also compared. A retrospective cohort analysis was conducted using prescription, professional fee claims, and hospital data. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. IPTW-adjusted Poisson regression was used to evaluate the adjusted rVE of aIIV3 versus HD-IIV3e. All-cause and influenza-related healthcare resource utilization (HCRU) and costs were examined post-IPTW. Recycled predictions from generalized linear models were used to estimate adjusted costs. Adjusted analysis showed that aIIV3 (n = 798,987) was similarly effective compared to HD-IIV3e (n = 1,655,979) in preventing influenza-related hospitalizations/ER visits (rVE 3.1%; 95% CI: −2.8%; 8.6%), hospitalizations due to any cause (−0.7%; 95% CI: −1.6%; 0.3%), and any CRD-related hospitalization/ER visit (0.9%; 95% CI: 0.01%; 1.7%). Adjusted HCRU and annualized costs were also statistically insignificant between the two cohorts. The adjusted clinical and economic outcomes evaluated in this study were comparable between aIIV3 and HD-IIV3e during the 2019–2020 influenza season. MDPI 2021-10-08 /pmc/articles/PMC8540032/ /pubmed/34696254 http://dx.doi.org/10.3390/vaccines9101146 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Levin, Myron J. Divino, Victoria Shah, Drishti DeKoven, Mitch Mould-Quevedo, Joaquin Pelton, Stephen I. Postma, Maarten J. Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis |
title | Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis |
title_full | Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis |
title_fullStr | Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis |
title_full_unstemmed | Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis |
title_short | Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis |
title_sort | comparing the clinical and economic outcomes associated with adjuvanted versus high-dose trivalent influenza vaccine among adults aged ≥ 65 years in the us during the 2019–20 influenza season—a retrospective cohort analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540032/ https://www.ncbi.nlm.nih.gov/pubmed/34696254 http://dx.doi.org/10.3390/vaccines9101146 |
work_keys_str_mv | AT levinmyronj comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis AT divinovictoria comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis AT shahdrishti comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis AT dekovenmitch comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis AT mouldquevedojoaquin comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis AT peltonstepheni comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis AT postmamaartenj comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis |